|Education||BS, Bridgewater State College|
|Current Position||Associate Professor|
Acute myeloid leukemia (AML) is a hematological malignancy with 12,000 new cases diagnosed annually in the United States. Of these patients, one third harbor mutations in the receptor tyrosine kinase FLT3. These mutations can lead to constitutive activation of the receptor or drug resistance, both associated with poor prognosis. Our lab studies the preclinical development of both small molecule inhibitors and monoclonal antibodies targeting FLT3. We test these drugs on our collection of primary patient blasts focusing on cytotoxicity, potency, and modifications of signal transduction.